AstraZeneca's latest push into oncology comes after its net profit almost doubled to $6 billion last year as a strong cancer division helped offset a wipeout for sales of its Covid treatments.
AstraZeneca's latest push into oncology comes after its net profit almost doubled to $6 billion last year as a strong cancer division helped offset a wipeout for sales of its Covid treatments.